Ironshore: Cayman’s nascent pharma giant

From left, Ironshore Pharmaceutical associate Kellie McGee, senior vice president Fiona McDougall, and CEO David Lickrish are in the final stages of bringing to market a new ADHD treatment, JORNAY PM. Lickrish thinks Cayman has the potential to be a jurisdiction of choice for pharma companies. – Photo: Ken Silva

Cayman is globally renowned for its tourism and financial services, but is not known for having a pharmaceutical industry.

That could change soon, however, if all goes according to plans that have been long in the works by the Cayman-registered company Ironshore Pharmaceuticals.

Working out of a third-story office at Camana Bay, Ironshore Pharmaceuticals’ seven staff members are working to bring to market a new drug that treats Attention Deficit Hyperactivity Disorder (ADHD).

The company’s drug, JORNAY PM, would allow for treatments to be administered at night, with the medication kicking in first thing the next morning. Currently, ADHD medication has to be dosed in the morning, and the consumer has to wait before he or she feels the effects of the drug.

In other words, this drug would help those who have ADHD with the all-important morning routine, said Ironshore CEO David Lickrish.

See The Journal’s website to read the rest of the story.

Support local journalism. Subscribe to the all-access pass for the Cayman Compass.

Subscribe now